- Report
- May 2024
- 129 Pages
Global
From €6160EUR$6,499USD£5,146GBP
- Report
- June 2024
- 200 Pages
Global
From €7535EUR$7,950USD£6,295GBP
- Report
- June 2024
- 200 Pages
Global
From €7535EUR$7,950USD£6,295GBP
- Report
- January 2022
- 60 Pages
Global
From €3744EUR$3,950USD£3,128GBP
- Report
- January 2022
- 60 Pages
Global
From €3744EUR$3,950USD£3,128GBP
- Clinical Trials
- April 2024
- 40 Pages
Global
From €1185EUR$1,250USD£990GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1896EUR$2,000USD£1,584GBP
- Report
- December 2022
- 279 Pages
Global
From €2370EUR$2,500USD£1,980GBP
- Clinical Trials
- September 2021
- 251 Pages
Global
From €2370EUR$2,500USD£1,980GBP
- Report
- May 2022
- 59 Pages
Global
From €1896EUR$2,000USD£1,584GBP
Rhinosinusitis is a condition that affects the sinuses and nasal passages, causing inflammation and congestion. It is often treated with medications that reduce inflammation and improve symptoms. These medications are part of the respiratory drugs market, which includes drugs used to treat a variety of respiratory conditions, such as asthma, COPD, and allergies.
The rhinosinusitis drug market includes a variety of medications, such as corticosteroids, decongestants, antihistamines, and antibiotics. These drugs are used to reduce inflammation, relieve congestion, and treat infections. They are available in a variety of forms, including tablets, capsules, liquids, and nasal sprays.
Some of the companies in the rhinosinusitis drug market include GlaxoSmithKline, Merck, Pfizer, Novartis, and Sanofi. These companies produce a range of medications for the treatment of rhinosinusitis, including corticosteroids, decongestants, antihistamines, and antibiotics. Show Less Read more